Welcome to our dedicated page for Envoy Medical news (Ticker: COCH), a resource for investors and traders seeking the latest updates and insights on Envoy Medical stock.
Envoy Medical, Inc. develops hearing-health technologies focused on fully implanted hearing solutions. The company’s portfolio includes the Esteem FI-AMEI, an FDA-approved fully implanted active middle ear implant for adults with moderate to severe sensorineural hearing loss, and the investigational Acclaim cochlear implant, which uses a sensor designed to work with the ear’s natural anatomy rather than an external microphone.
Recurring company news covers Acclaim clinical-study updates, FDA-related development toward a Premarket Approval pathway, financial results, capital-structure actions, Nasdaq listing compliance, board and governance changes, and intellectual-property updates tied to its hearing segment.
Envoy Medical (NASDAQ: COCH) reported second quarter 2026 results and regulatory progress for its fully implanted Acclaim cochlear implant. The company submitted the first of four modules of its modular PMA application to the FDA and targets submission of the final, clinical-data module in Q2 2027.
According to Envoy Medical, 12‑month Stage 1 data from the first 10 pivotal trial participants showed mean CNC word recognition improving to 53.2% from a 15.2% pre‑implant baseline, and the full cohort has passed the three‑month follow‑up window. Net revenue for Q2 2026 was $51,000, with a net loss attributable to common stockholders of $7.3 million, or $0.07 per share. Envoy ended June 30, 2026 with $19.7 million in cash and positive stockholders’ equity of $3.3 million, aided by approximately $30.0 million of gross financing proceeds in the first half and new patents granted in Australia and Europe.
Envoy Medical (NASDAQ: COCH) reported that all 56 patients in its pivotal clinical trial of the investigational fully implanted Acclaim cochlear implant have surpassed the three-month visit milestone. The company continues collecting safety and other study measures for inclusion in a planned Premarket Approval (PMA) submission to the U.S. FDA.
According to Envoy Medical, the six-month visit milestone is anticipated by late 2026, with the 12-month visit milestone for the entire study expected by April 2027. The Acclaim CI, which leverages the ear’s natural anatomy instead of a microphone, holds FDA Breakthrough Device Designation and targets adults with severe to profound sensorineural hearing loss not adequately addressed by hearing aids.
Envoy Medical (NASDAQ: COCH) reported 12‑month interim results from the first 10 participants in Stage 1 of its pivotal trial of the investigational fully implanted Acclaim cochlear implant. Mean CNC word recognition improved to 53.2% from 15.2% pre‑implant, a 38.0 percentage point gain, versus a 39.2% mean score at six months.
Nine of 10 participants showed a positive hearing response; excluding one potential non‑responder, mean CNC scores reached 59.1%, a 42.2 percentage point increase. No protocol‑defined serious adverse events were reported through 12 months. Stage 2 of the trial is fully enrolled, with all 12‑month data expected by early Q2 2027 and a PMA submission to the FDA planned a few months thereafter.
Envoy Medical (NASDAQ: COCH) submitted the first module of its modular Premarket Approval (PMA) application to the FDA for its Breakthrough Device-designated Acclaim cochlear implant. The plan includes four modules, with the final clinical module targeted for Q2 2027, supporting ongoing FDA interaction and clearer investor milestones.
Envoy Medical (NASDAQ: COCH), a hearing health company focused on fully implanted hearing solutions, announced it has terminated its at-the-market equity facility.
The ATM facility had allowed the company to offer and sell up to $15 million of common stock and was terminated effective June 24, 2026. Envoy Medical indicated the termination reflects confidence in its current capital position.
Envoy Medical (NASDAQ: COCH) announced that CEO Brent Lucas will present at two investor events on June 25, 2026.
He will speak at the Life Sciences Virtual Investor Forum at 1:00 p.m. ET and the Biotech Webull Webinar Panel at 2:40 p.m. ET, both accessible via webcast links.
Envoy Medical (NASDAQ: COCH) announced that CEO Brent Lucas will present at the Planet MicroCap Conference Las Vegas 2026 from June 16-18 at the Bellagio Hotel & Casino.
The presentation is scheduled for Wednesday, June 17, 2026 at 11:00 A.M. PT in Track 7 - Donatello 3, with a webcast available.
Envoy Medical (NASDAQ: COCH) announced four newly granted patents in Australia and Europe and an additional European patent expected June 10, 2026. The intellectual property covers fully implanted cochlear implant platforms, removable earplug sensors, integrated signal analysis, implanted battery systems, and rechargeable battery safety and management.
Envoy Medical (NASDAQ: COCH) reported Q1 2026 results and key milestones advancing its investigational fully implanted Acclaim cochlear implant toward FDA PMA submission.
Highlights include completion of pivotal trial enrollment (56 patients), an upsized public offering of up to $78.0 million, promising interim clinical data, and cash of approximately $25,251 as of March 31, 2026.
- Interim data from first 10 patients showed improved word recognition and no study-defined serious adverse events.
- Global IP portfolio expanded to 47 patents.
- All 56 patients activated; first three reached 12‑month endpoint.
Envoy Medical (NASDAQ: COCH) presented interim six-month clinical data from the first 10 patients in its pivotal study of the investigational Acclaim cochlear implant. Key findings: no study-defined serious adverse events, mean CNC word recognition improved from 15.2% to 39.2%, median daily device wear time 24 hours, and quality-of-life and tinnitus scores improved.
Additional podium presentations are scheduled for May 8 and May 11, 2026, and a company fireside chat is set for April 29, 2026 at 4:30 PM ET.